481704-21-6

481704-21-6 structure

Name: tans-4-Hydroxy-D-proline methyl ester hydrochloride
Chemical Name: (2R,4S)-Methyl 4-hydroxypyrrolidine-2-carboxylatehydrochloride
CAS Number: 481704-21-6
Molecular Formula: C₆H₁₂ClNO₃
Molecular Weight: 181.617
Catalog: Biochemical Amino acids and their derivatives Proline derivatives
Create Date: 2018-12-24 16:59:11
Modify Date: 2024-01-09 18:22:11
tans-4-Hydroxy-D-proline methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].

Name	(2R,4S)-Methyl 4-hydroxypyrrolidine-2-carboxylatehydrochloride
Synonyms	Trans-4-hydroxy-L-proline methyl ester hydrochloride 1-Hydroxy-pentan-2-on Methyl (4R)-4-hydroxy-L-prolinate hydrochloride (1:1) 1-hydroxy-pentan-2-one Hydroxymethyl-propyl-keton 1-Hydroxy-2-pentanone 2-Pentanone,1-hydroxy l-hydroxy-2-oxopentane L-hydroxyproline methyl ester hydrochloride L-Proline, 4-hydroxy-, methyl ester, (4R)-, hydrochloride (1:1) 4S-hydroxy-1-pyrrolidine-2R-carboxylic acid methyl ester hydrochloride salt 1-hydroxy-2-oxopentane

Description	tans-4-Hydroxy-D-proline methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker
Target	Non-cleavable
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
References	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

3398-22-9

~85%

481704-21-6

Literature: WO2003/104249 A1, ; Page 14 ;

647857-51-0

481704-21-6

Literature: WO2004/7444 A2, ; Page 141 ;

67-56-1

142347-81-7

481704-21-6

Literature: WO2013/49164 A1, ; Paragraph 838-839 ;

Precursor 4
3398-22-9 647857-51-0 67-56-1 142347-81-7
DownStream 0